Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ATXI

ATXI - Avenue Therapeutics Inc Stock Price, Fair Value and News

0.15USD0.00 (0.00%)Delayed as of 21 Feb 2024, 01:57 pm ET
Watchlist

Market Summary

USD0.150.00
Delayedas of 21 Feb 2024, 01:57 pm
0.00%

ATXI Stock Price

View Fullscreen

ATXI RSI Chart

ATXI Valuation

Market Cap

2.0M

Price/Earnings (Trailing)

-0.19

Price/Free Cashflow

-0.18

ATXI Price/Sales (Trailing)

ATXI Profitability

Return on Equity

-11.98%

Return on Assets

-2.1K%

Free Cashflow Yield

-568.45%

ATXI Fundamentals

ATXI Earnings

Earnings (TTM)

-10.5M

Earnings Growth (Yr)

177.49%

Earnings Growth (Qtr)

112.77%

Breaking Down ATXI Revenue

52 Week Range

0.141.36
(Low)(High)

Last 7 days

7.1%

Last 30 days

-11.8%

Last 90 days

-25%

Trailing 12 Months

-87.6%

How does ATXI drawdown profile look like?

ATXI Financial Health

ATXI Investor Care

Shares Dilution (1Y)

177.53%

Tracking the Latest Insider Buys and Sells of Avenue Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 02, 2024
fortress biotech, inc.
acquired
-
-
2,101,500
-
Dec 11, 2023
davidow robert l
sold
-36,960
0.14
-264,000
-
Dec 11, 2023
davidow robert l
sold
-2,800
0.14
-20,000
-
Dec 11, 2023
davidow robert l
sold
-2,700
0.15
-18,000
-
Dec 11, 2023
davidow robert l
sold
-17,640
0.14
-126,000
-
Dec 11, 2023
davidow robert l
sold
-17,920
0.14
-128,000
-
Dec 11, 2023
davidow robert l
sold
-8,540
0.14
-61,000
-
Sep 08, 2023
fortress biotech, inc.
bought
301,255
0.72
418,410
-
Sep 08, 2023
rosenwald lindsay a md
bought
251,046
0.72
348,675
-
Mar 31, 2023
fortress biotech, inc.
acquired
-
-
52,419
-

1–10 of 45

Which funds bought or sold ATXI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
STATE STREET CORP
unchanged
-
-16,560
4,971
-%
Feb 14, 2024
Cubist Systematic Strategies, LLC
new
-
1,756
1,756
-%
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
added
90.47
-5,780
4,428
-%
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
new
-
4,648
4,648
-%
Feb 14, 2024
VANGUARD GROUP INC
unchanged
-
-25,276
7,453
-%
Feb 14, 2024
Royal Bank of Canada
added
424
-
-
-%
Feb 14, 2024
CITADEL ADVISORS LLC
new
-
14,405
14,405
-%
Feb 13, 2024
BlackRock Inc.
reduced
-32.71
-1,119
202
-%
Feb 13, 2024
MORGAN STANLEY
sold off
-100
-195
-
-%

1–10 of 21

Are Funds Buying or Selling ATXI?

Are funds buying ATXI calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ATXI
No. of Funds

Unveiling Avenue Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 02, 2024
sabby management, llc
4.99%
661,056
SC 13G/A
Dec 13, 2023
davidow robert l
9.89%
1,309,800
SC 13G/A
Nov 28, 2023
davidow robert l
14.5%
1,926,800
SC 13G
Sep 18, 2023
fortress biotech, inc.
12.1%
1,049,056
SC 13D/A
Feb 14, 2023
cvi investments, inc.
4.9%
251,011
SC 13G/A
Jan 06, 2023
fortress biotech, inc.
11.3%
578,227
SC 13D/A
Jan 04, 2023
sabby management, llc
5.53%
264,000
SC 13G
Dec 14, 2022
nantahala capital management, llc
0.0%
0
SC 13G/A
Oct 19, 2022
invagen pharmaceuticals, inc.
0%
0
SC 13D/A
Oct 17, 2022
intracoastal capital, llc
4.99%
4
SC 13G

Recent SEC filings of Avenue Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 02, 2024
424B3
Prospectus Filed
Feb 01, 2024
EFFECT
EFFECT
Jan 29, 2024
DEF 14C
DEF 14C
Jan 24, 2024
S-3
S-3
Jan 17, 2024
PRE 14C
PRE 14C
Jan 12, 2024
8-K
Current Report
Jan 08, 2024
8-K
Current Report
Jan 03, 2024
4
Insider Trading
Jan 02, 2024
SC 13G/A
Major Ownership Report
Dec 13, 2023
SC 13G/A
Major Ownership Report

Peers (Alternatives to Avenue Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.2B
9.1B
-16.59% -47.80%
-9.57
3.64
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
18.9B
1.8B
-23.99% -31.71%
-42.82
10.31
76.23% 61.08%
16.7B
2.3B
-4.89% -18.90%
113.61
7.23
15.05% 75.21%
13.2B
3.7B
-7.62% -26.87%
22.1
3.57
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.27
29.46
141.38% 4.43%
6.3B
107.9M
-3.85% 226.12%
-10.03
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-19.02
17.18
-35.86% -26.24%
3.6B
240.7M
-19.08% -10.99%
-12.2
15.04
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.7
4.22
81.69% -7.29%
490.6M
1.0B
-9.17% -57.89%
-0.89
0.47
-43.15% 58.48%
185.9M
4.9M
-14.18% -58.18%
-1.13
38.02
-57.57% 50.48%
103.1M
881.7K
289.54% 381.25%
-2.17
112.79
-77.61% -13.74%
4.4M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Avenue Therapeutics Inc News

Latest updates
Seeking Alpha24 Jan 202409:22 pm

Avenue Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-69.9%5021,6668,4476,8455751,0051,9563,9606881,1911,9443,2454,3525,3316,6968,91513,87815,67729,7634,5255,263
    Cash Equivalents-89.8%1611,5718,2366,7082179001,8003,7635851,1211,8253,1324,3255,2576,5748,7458,74110,45529,4482,6714,804
Liabilities-35.7%5,0247,81210,6043,5796144077975098485494698861,1181,2309232,1151,9171,7739,4125,1562,469
  Current Liabilities-35.7%5,0247,81210,6043,5796144077975098485494698861,1181,2309232,1151,9171,7739,4125,1562,469
Shareholder's Equity1.3%87,91786,75786,6343,90581,0875981,1593,45175,9246421,4752,3593,2344,1015,7736,80011,96113,90420,35141,5772,794
  Retained Earnings0.5%-91,600-92,100-88,100-80,551-81,126-80,500-79,860-76,999-76,086-75,215-74,266-73,268-72,275-71,247-69,359-68,117-62,702-60,460-53,478-42,209-38,290
  Additional Paid-In Capital1.3%87,91786,75786,63484,45681,08781,06081,01780,45075,92475,85575,73975,62575,50775,34675,13074,91574,66174,36273,82741,57741,083
Shares Outstanding13.2%8,9647,9206,8284,7741,4661,4761,3971,4061,1081,1041,1041,1171,099--------
Minority Interest-7.7%-872-810-705-639-----------------
Float------2,946---16,813---72,343---40,871---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations80.9%-889-4,665-1,573-4,169-554-943-1,930-1,203-536-704-1,307-1,193-932-1,317-1,171-4,996-1,714-13,981-5,568-1,238-4,136
  Share Based Compensation1977.8%56127.0011.0012.0025.0043.0056914369.00116114118161216215254299535751491400
Cashflow From Investing-Infinity%-1,000--------------1,0005,000--5,000---
Cashflow From Financing-479-3,10110,660-119-------------12.0032,345-895-

ATXI Income Statement

2023-09-30
Unaudited Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:    
Research and development$ 907$ 194$ 5,149$ 2,153
Research and development – licenses acquired004,2300
General and administrative1,1614693,0421,978
Loss from operations(2,068)(663)(12,421)(4,131)
Other income (expense):    
Interest income911044
Financing costs – warrant liabilities00(332)0
Change in fair value of warrant liabilities2,57201,5440
Total other income (expense)2,58111,3164
Net income (loss)513(662)(11,105)(4,127)
Net income (loss) attributable to non-controlling interests(13)0(88)0
Net income (loss) attributable to common stockholders$ 526$ (662)$ (11,017)$ (4,127)
Net income (loss) per common share attributable to common stockholders:    
Basic (in dollars per share)$ 0.06$ (0.45)$ (1.54)$ (2.86)
Diluted (in dollars per share)$ 0.06$ (0.45)$ (1.54)$ (2.86)
Basic (in shares)8,114,1551,465,6917,155,0501,441,542
Diluted (in shares)8,200,0691,465,6917,155,0501,441,542

ATXI Balance Sheet

2023-09-30
Unaudited Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 161$ 6,708
Deferred financing costs3100
Prepaid expenses and other current assets18137
Total assets5026,845
Current Liabilities:  
Accounts payable and accrued expenses1,460949
Warrant liability3,3002,609
Total current liabilities5,0243,579
Total liabilities5,0243,579
Commitments and contingencies
Stockholders’ equity (deficit)  
Common stock ($0.0001 par value), 75,000,000 shares authorized Common shares, 6,828,186 and 4,773,841 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively10
Additional paid-in capital87,91784,456
Accumulated deficit(91,568)(80,551)
Total stockholders’ equity attributed to the Company(3,650)3,905
Non-controlling interests(872)(639)
Total stockholders’ equity (deficit)(4,522)3,266
Total liabilities and stockholders’ equity5026,845
Preferred Class A [Member]  
Stockholders’ equity (deficit)  
Preferred stock ($0.0001 par value), 2,000,000 shares authorized Class A Preferred Stock, 250,000 shares issued and outstanding as of March 31, 2023 and December 31, 202200
Related Party [Member]  
Current assets:  
Other receivables - related party130
Current Liabilities:  
Accounts payable and accrued expenses1,460949
Nonrelated Party [Member]  
Current Liabilities:  
Accounts payable and accrued expenses$ 264$ 21
ATXI
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.
 CEO
 WEBSITEwww.avenuetx.com
 EMPLOYEES2

Avenue Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Avenue Therapeutics Inc? What does ATXI stand for in stocks?

ATXI is the stock ticker symbol of Avenue Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avenue Therapeutics Inc (ATXI)?

As of Tue Feb 20 2024, market cap of Avenue Therapeutics Inc is 1.99 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATXI stock?

You can check ATXI's fair value in chart for subscribers.

What is the fair value of ATXI stock?

You can check ATXI's fair value in chart for subscribers. The fair value of Avenue Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avenue Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATXI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Avenue Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ATXI is over valued or under valued. Whether Avenue Therapeutics Inc is cheap or expensive depends on the assumptions which impact Avenue Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATXI.